Intra-Cellular Therapies

• CAPLYTA is at peak sales with strong Part D reimbursement ($195M), providing revenue stability and ongoing commercial momentum across schizophrenia, bipolar disorder, and MDD.
• Robust pipeline of 41 active programs with 18 Phase 3 trials, including multiple expansions of lumateperone into autism irritability, MDD, and bipolar mania—near-term catalysts are likely.
• Neurology focus in high-need therapeutic areas (schizophrenia, bipolar, Alzheimer's agitation) with diverse mechanistic approaches (dopamine/serotonin modulation, novel targets via ITI-007, ITI-1284, ITI-333) offers deep clinical impact.

Generated by Claude from Intra-Cellular Therapies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Foundation of company revenue with 16+ years of exclusivity; multiple phase 3 label-expansion trials underway in MDD, bipolar mania, and autism irritability.